Lung Cancer clinical trials in Idaho

9 actively recruiting lung cancer trials at 10 sites across Idaho.

Data from ClinicalTrials.gov · last refreshed 2026-10-19

Phase 2, Phase 3 Recruiting Network

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT03851445

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Walter Knox Memorial Hospital — Emmett, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06498635

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07388524

Sites in Idaho:

Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho
Kootenai Clinic Cancer Services - Sandpoint — Sandpoint, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …

Sponsor: AstraZeneca

NCT ID: NCT06692738

Sites in Idaho:

Research Site — Boise, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approa…

Sponsor: Canadian Cancer Trials Group

NCT ID: NCT06686771

Sites in Idaho:

Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
Saint Luke's Cancer Institute - Nampa — Nampa, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…

Sponsor: Bristol-Myers Squibb

NCT ID: NCT06561386

Sites in Idaho:

Local Institution - 0509 — Coeur d'Alene, Idaho

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…

Sponsor: Merck Sharp & Dohme LLC

NCT ID: NCT06623422

Sites in Idaho:

Beacon Cancer Care ( Site 0127) — Post Falls, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting Network

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05642572

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Saint Alphonsus Cancer Care Center-Nampa — Nampa, Idaho
Kootenai Clinic Cancer Services - Post Falls — Post Falls, Idaho

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib …

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT03191149

Sites in Idaho:

Saint Alphonsus Cancer Care Center-Boise — Boise, Idaho
Saint Luke's Cancer Institute - Boise — Boise, Idaho
Saint Alphonsus Cancer Care Center-Caldwell — Caldwell, Idaho
Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
Walter Knox Memorial Hospital — Emmett, Idaho

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19